Three years after navigating the Humira patent cliff, AbbVie CEO Robert Michael declares the company’s position is “stronger than ever.” This confidence is anchored by the record-breaking performance of Skyrizi and a surging neuroscience franchise.
1. Skyrizi’s Meteoric Rise
Skyrizi is effectively succeeding Humira as AbbVie’s star performer. In Q1 2026, it generated $4.48 billion in sales (30.9% growth), nearly matching Humira’s historical peak quarterly haul.
-
Competitive Edge: Its quarterly dosing schedule and durable efficacy provide a “distinct advantage” over existing psoriasis therapies.
-
2026 Outlook: Net revenues for Skyrizi are now projected at $21.6 billion for the full year, driven by robust demand in both psoriasis and inflammatory bowel disease (IBD) sectors.
2. Countering J&J’s Icotyde
The recent launch of J&J’s Icotyde, a once-daily oral pill for psoriasis, has been labeled a potential “game-changer.” AbbVie, however, remains skeptical:
-
Efficacy Disparity: AbbVie leadership asserts that Icotyde’s efficacy parameters are “quite a bit lower” than Skyrizi’s when matched against controlled populations.
-
Market Scope: Skyrizi is already a leader in Psoriatic Arthritis (PsA), whereas Icotyde currently lacks clinical evidence in this significant value-driving market.
-
Adherence Issues: AbbVie notes that oral daily adherence in psoriasis treatment presents complexities that long-acting injectables do not face.
3. Neuroscience: The Next Frontier
Beyond immunology, AbbVie’s neuroscience franchise collected $2.87 billion in Q1 2026.
-
Vyalev: The Parkinson’s disease treatment earned $201 million this quarter and is on track to exceed $1 billion in annual sales.
-
Vraylar: Generated $905 million, maintaining significant leadership in treating bipolar and major depressive disorders.
Conclusion
With total Q1 sales of $15 billion (up 12.4%), AbbVie has raised its full-year 2026 sales guidance to $67.3 billion. The company continues to position itself as a global leader in immunology and neuroscience, backed by a pipeline capable of delivering transformational improvements over current standards of care.